Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens

[1]  J. A. Guerra-Assunção,et al.  Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection , 2024, Virus evolution.

[2]  T. Peacock,et al.  A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes , 2023, Nature.

[3]  Mariana Lenharo.  WHO declares end to COVID-19’s emergency phase , 2023, Nature.

[4]  C. Wrenger,et al.  Virulence Profiles of Wild-Type, P.1 and Delta SARS-CoV-2 Variants in K18-hACE2 Transgenic Mice , 2023, Viruses.

[5]  Michael R Hamblin,et al.  Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? , 2023, Biomedicine & Pharmacotherapy.

[6]  A. Casadevall,et al.  Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics , 2023, International Journal of Antimicrobial Agents.

[7]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.

[8]  K. Rosenke,et al.  Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques , 2022, bioRxiv.

[9]  V. Hu,et al.  The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations , 2022, Medicinal Chemistry Research.

[10]  C. Yasuda,et al.  Morphological, cellular, and molecular basis of brain infection in COVID-19 patients , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Y. Choi,et al.  Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice , 2022, bioRxiv.

[12]  P. Uchil,et al.  The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice , 2022, bioRxiv.

[13]  A. Webb,et al.  Caspase-4/11 exacerbates disease severity in SARS–CoV-2 infection by promoting inflammation and immunothrombosis , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Rosenke,et al.  Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model , 2022, JCI insight.

[15]  B. Clotet,et al.  Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice , 2022, Frontiers in Microbiology.

[16]  R. Wiegand,et al.  Public health impact of covid-19 vaccines in the US: observational study , 2022, BMJ.

[17]  Howard D Larkin.  Global COVID-19 Death Toll May Be Triple the Reported Deaths. , 2022, JAMA.

[18]  J. Kublin,et al.  COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective , 2022, Open forum infectious diseases.

[19]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[20]  Yahiya Y. Syed.  Molnupiravir: First Approval , 2022, Drugs.

[21]  P. Uchil,et al.  Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2’s evasive maneuvering , 2022, Cell Reports Medicine.

[22]  T. Wallach,et al.  Persistent SARS-CoV-2 Nucleocapsid Protein Presence in the Intestinal Epithelium of a Pediatric Patient 3 Months After Acute Infection , 2021, JPGN reports.

[23]  M. C. Muenker,et al.  De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report , 2021, Nature Communications.

[24]  Junfen Fan,et al.  The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era , 2021, The Lancet Microbe.

[25]  B. Weynand,et al.  The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model , 2021, EBioMedicine.

[26]  R. Baric,et al.  Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy , 2021, Nature.

[27]  L. Stamatatos,et al.  Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy , 2021, Immunity.

[28]  S. Fukushi,et al.  Favipiravir treatment prolongs the survival in a lethal mouse model intracerebrally inoculated with Jamestown Canyon virus , 2021, PLoS neglected tropical diseases.

[29]  H. Schuitemaker,et al.  Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans , 2021, Nature.

[30]  A. Pyke,et al.  A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses , 2021, Nature Communications.

[31]  V. Préat,et al.  An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. , 2021, Advanced drug delivery reviews.

[32]  Tesia M. Bobrowski,et al.  Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 , 2020, Molecular Therapy.

[33]  T. Kohlsdorf,et al.  Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients , 2020, The Journal of experimental medicine.

[34]  A. Boretti.  Favipiravir use for SARS CoV-2 infection , 2020, Pharmacological Reports.

[35]  Fabian J. Theis,et al.  Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis , 2020, Nature Communications.

[36]  L. Mao,et al.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. , 2020, JAMA neurology.

[37]  Christopher R Bilder,et al.  Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources , 2020, medRxiv.

[38]  T. Aittokallio,et al.  SynergyFinder 2.0: visual analytics of multi-drug combination synergies , 2020, Nucleic Acids Res..

[39]  A. Goel,et al.  Emerging prophylaxis strategies against COVID-19. , 2020, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[40]  Shery Jacob,et al.  A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.

[41]  Allen Caldwell,et al.  Panel , 1991, 2021 IEEE International Conference on Pervasive Computing and Communications (PerCom).

[42]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .